Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Balsa

Showing results (121-130 of 246) with videos related to

Pageof 25
Sort By:
Arthritis and Rheumatism|March 10, 2010
Deletion of the late cornified envelope genes, LCE3C and LCE3B, is associated with rheumatoid arthritisElisa Docampo, Raquel Rabionet, Eva Riveira-Muñoz, et al.
BMJ Open|April 29, 2022
Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in SpainDiego Benavent, Karen Franco-Gómez, Chamaida Plasencia-Rodriguez, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximabChamaida Plasencia, Dora Pascual-Salcedo, Laura Nuño, et al.
Rheumatology and Therapy|October 13, 2024
Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A CommentaryPeter C Taylor, Alejandro Balsa, Anne-Barbara Mongey, et al.
Arthritis and Rheumatism|August 1, 2008
Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibilityAntonio Julià, Javier Ballina, Juan D Cañete, et al.
Frontiers in Medicine|October 27, 2015
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice ConditionsChamaida Plasencia, Teresa Jurado, Alejandro Villalba, et al.
Annals of the Rheumatic Diseases|December 5, 2020
Correspondence on: 'EULAR definition of difficult-to-treat rheumatoid arthritis'Marta Novella-Navarro, Chamaida Plasencia-Rodríguez, Carolina Tornero, et al.
Plos One|August 8, 2012
Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivityIrene Arroyo-Villa, María-Belén Bautista-Caro, Alejandro Balsa, et al.
Arthritis Research & Therapy|September 4, 2009
Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritisRaimon Sanmartí, Eduard Graell, Maria L Perez, et al.
Arthritis Research & Therapy|July 30, 2013
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patientsChamaida Plasencia, Dora Pascual-Salcedo, Sara García-Carazo, et al.
Pageof 25

Showing results (121-130 of 246) with videos related to

Sort By:
Pageof 25
Arthritis and Rheumatism|March 10, 2010
Deletion of the late cornified envelope genes, LCE3C and LCE3B, is associated with rheumatoid arthritisElisa Docampo, Raquel Rabionet, Eva Riveira-Muñoz, et al.
BMJ Open|April 29, 2022
Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in SpainDiego Benavent, Karen Franco-Gómez, Chamaida Plasencia-Rodriguez, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximabChamaida Plasencia, Dora Pascual-Salcedo, Laura Nuño, et al.
Rheumatology and Therapy|October 13, 2024
Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A CommentaryPeter C Taylor, Alejandro Balsa, Anne-Barbara Mongey, et al.
Arthritis and Rheumatism|August 1, 2008
Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibilityAntonio Julià, Javier Ballina, Juan D Cañete, et al.
Frontiers in Medicine|October 27, 2015
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice ConditionsChamaida Plasencia, Teresa Jurado, Alejandro Villalba, et al.
Annals of the Rheumatic Diseases|December 5, 2020
Correspondence on: 'EULAR definition of difficult-to-treat rheumatoid arthritis'Marta Novella-Navarro, Chamaida Plasencia-Rodríguez, Carolina Tornero, et al.
Plos One|August 8, 2012
Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivityIrene Arroyo-Villa, María-Belén Bautista-Caro, Alejandro Balsa, et al.
Arthritis Research & Therapy|September 4, 2009
Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritisRaimon Sanmartí, Eduard Graell, Maria L Perez, et al.
Arthritis Research & Therapy|July 30, 2013
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patientsChamaida Plasencia, Dora Pascual-Salcedo, Sara García-Carazo, et al.
Pageof 25